Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy

Trial Profile

(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levacecarnine (Primary) ; Prednisolone; Prednisone; Sagopilone
  • Indications Peripheral neuropathies
  • Focus Therapeutic Use
  • Acronyms REASON
  • Sponsors Bayer; Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
    • 31 Aug 2018 Biomarkers information updated
    • 08 Feb 2017 New source identified and integrated (ISRCTN75009754; ISRCTN: Current Controlled Trials).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top